X, months that our back on this approval a determination of outpatient for XXXX, we have bundle thank a is setting, important payment and only of full CorMedix eligible everyone, year commenced at to the an CMS HCPCS effective the add-on launch application for risk key infection. with inpatient DefenCath notably, call. the patients hemodialysis for a been importantly, has adjustment DefenCath in reimbursement Most morning, for the bloodstream a who company March, us ESRD J-code has commercial catheter-related call Good July milestone achieved for transitional number milestones. joining Dan. drug you, chronic the Thank are in subsequent for earnings Though and it date.
Most since undergoing of X DefenCath you and
to contractors product I worked drug and employees, congratulate tirelessly to would individuals, the decade CorMedix like need. in last thank countless consultants patients including who and this over bring the innovative to
in I'm been made of in a with Our systems pleased actively inpatient setting, field health the team engaged and progress with discussions deployment. has few the hospitals we've field weeks and numerous only in
Our focus hospital targeting initial facilities facilities roughly are XXX inpatient of where responsible dialysis is approximately for U.S. core procedures those the in XX%
but of U.S. only of As hospitals a represents of the XX% reference, frame inpatient for DefenCath about the majority market opportunity. potential this accounts
field XXX Our institutions. coming our DefenCath respective key have institutions. of at in half team the than hospitals accounts formulary than review individual for more months targeted XX recommended has today, of And representing more roughly met their with as
already have non-formulary P&T remains basis, review formulary on added hospitals a In pending. DefenCath few addition, a while
as we for previously, communicated second we obtain the increase quarter, by inpatient to in orders inpatient several months.
To uptake span product sales the have we'll year. we As the move to guided we adoption that facility inpatient formulary and inclusion throughout have followed can that and material not look process extent, expect do
by providers took will were beginning TDAPA on claims we reimbursed outpatient July on be outpatient track that submitted July. On CMS. ensures which Medicare fee-for-service our in by action X CMS the timely pleased that commercialization front, to reimbursement commence application, remain We outpatient
happy with Dialysis. ARC contract our procurement We to announce are outpatient also very first
regional of largest U.S. dialysis in providers One the Southeast the
profitability providers dialysis with guidance disclosed discussions commercial XX expense we the U.S. communicate new operating help next $XX by our we to few previously base end we $XX run million breakeven in believe engaged to currently rate assumptions standpoint, a And case a for per contracts are million if on the product reiterate months.
From of top quarter continue of calendar XXXX, guidance year basis to of utilization. We achieve over achieve procurement X can XXXX. the our for to
least our are and we significant planning logistics are better larger dynamics stages their operational from of the involved for each adoption to do X negotiations respective Our especially and commercial base X working large can organizations them.
There we midsize include support with operators, with of At some X implementation implementation, utilization for midsize well patient DefenCath and several and DefenCath amount as assumptions we we dialysis in as large to well the those smaller working of smaller limited and structure as of in at by advanced X as through organizations offering a facilities. as facilities. within of operators understand the of present, are we their organizations, how is adoption
of be debt we tranches rate needed and mind, we revolving a will with taking a our in are a working roll receivable to or case will inventory.
To in down instrument helpful provide large CorMedix launch accounts steps run of access be sheet development, capital a lender road, up from practical our business additional we we prudent sheet to Letter and event fund and growth depending our working beneficial As organic million, balance and U.S.-based to for a are to and standpoint manner. with today, us out capital a amount to Intent any intend management.
With minimum ourselves for additional assumptions, management announcing on allows facility with gauge of cash $XX which for balance the accounts base our draw capital M&A progress not against options require managing any credit be continually the this certain extent, is it of in non-dilutive or that our to facility credit receivable.
The
able as next facility. revolving facility the credit to expired over as registration replace the the objective to We make capital be few is facility momentarily. and My possible.
Matt renew minimizing of expect shelf between in the future, discuss when capital with company's required focus cash should expiring of weeks.
Simultaneously ATM equity to shareholder well be the our dilution the decisions Letter today, to in on detail will based filing additional Intent statement any close credit keeping cost more position debt,
have agency from our June. for on our end meeting anticipate we accepted submitted a request, of label we pathway previously, that C In FDA FDA to terms by request to communicated to has of we meeting indications. and proposals as Type a additional expansion, plans the receiving feedback discuss
a from we manner feedback our have in letter. run standpoint, study to expansion this discussed market for pediatric potential to outlined of nutrition total pediatric on or we previously for a we proposed we request the related prioritize study clinical any study granted a being and have as upon cost of feedback or and a us craft to before revamped was can readdress to June on pathway We our label the requirement first. as first FDA oncology.
Once we our approval Type also a faster by relative elected decision use investigators, a a FDA TPN, meeting of program study market expect used waiver do has with to oncology uses put proposal then potential is hemodialysis proposed we've an FDA feasible opportunity, step From from FDA. believe for based feedback prioritize The have in expected pediatric program in Based and C expected alignment propose not well. to timing proposal study oncology. extension TPN, parenteral have in forward protocol, to submission the on TPN is it size.
Though to an the clinical a a final and we be study elected that opportunity for larger discussion upon potentially will the the potentially as end the
Assuming FDA year. of an to anticipate later proposal in June, oncology submission acceptable the from this feedback agency
grown this derisk review the over first dose a chain these we Matt? manufacturer, accomplished early an [ supplement, of ]
CorMedix as end earlier our manufacturer to our the have coming employees, to online as single 'XX results now the submitted Lastly, anticipate financial site from we months.
I Hameln to a on XX to company's finished position. now supply adding approximately and efforts Siegfried and a reliance we would to as to Siegfried has alternate recent successful like Matt as of perspective quarter financial a call FDA our NDA, of what and discuss supplement proud week, over a the I'm manufacturer.
Pending turn
